Cold Chain LogisticsSilver report
Published April 2026Insight Research12 min read2026 Edition12 sources, 12 primary-gradeStrong source depth

Thailand Cold-Chain Pharma, Vaccine Deep Dive

Thai cold-chain pharma ~THB 18-25B. DHL Pharma, Kuehne+Nagel, Yusen, SCGJWD, DKSH, Zuellig. Ambient, refrigerated, frozen, ultra-cold mRNA-vaccine.

Key takeaways

  1. 1

    Thai cold-chain pharma, vaccine logistics ~ FY2024.

  2. 2

    Temperature mix: ambient-controlled 15-25Β°C ~, refrigerated 2-8Β°C ~, frozen -20-30Β°C ~, ultra-cold -70-80Β°C ~, cryo+specialty ~.

  3. 3

    Operators: DHL Supply Chain Pharma, Kuehne+Nagel KN PharmaChain, Yusen, Nippon Express, SCGJWD, DKSH Healthcare, Zuellig Pharma, LF Logistics.

  4. 4

    GPO state vaccine, biologics production, cold-chain integration; Thai FDA, GDP, WHO PQS, IATA CEIV regulate.

  5. 5

    Drivers: COVID-19 vaccine, mRNA, biologics, insulin/GLP-1, clinical-trial, biosimilar, medical-tourism structural growth.

Executive summary

Thai cold-chain pharma, vaccine logistics market reaches ~ FY2024 covering temperature-controlled storage, transport, distribution, last-mile of pharmaceutical, vaccine, biologics, diagnostic, clinical-trial product. Categories by temperature: ambient-controlled (15-25Β°C) ~ of value covering most oral solid, liquid pharmaceutical products requiring controlled-room-temperature; refrigerated (2-8Β°C) ~ covering most vaccines, insulin, biologics, GLP-1, monoclonal antibody, protein therapy; frozen (-20Β°C to -30Β°C) ~ covering selective vaccine, biologic, sample; ultra-cold (-70Β°C to -80Β°C) ~ covering mRNA-vaccine (Pfizer-BioNTech, Moderna COVID), advanced biologics, cell therapy; cryo, specialty, clinical-trial ~ covering frozen tissue, cell-bank, research sample.[, , ]

Operators: DHL Supply Chain Pharma, DHL eCommerce Thailand (Deutsche Post DHL) β€” global leader in cold-chain pharma, ultra-cold mRNA-vaccine, dedicated facility, IATA CEIV certified. Kuehne+Nagel KN PharmaChain, KN PharmaCare β€” Swiss multinational global cold-chain pharma, vaccine integrated. Yusen Logistics Pharma, Nippon Express Pharma (Japanese NX Group, NYK Group) β€” Japanese auto-OEM-pharma adjacency, Thai-Japanese MNC, tier-2 cold-chain. SCGJWD Logistics (post-2023 SCG-JWD merger) β€” Thai-corporate cold-chain pharma, vaccine, biologics integrated; WHA Pharmaceutical industrial estate, warehouse-for-rent. DKSH Healthcare Thailand, LF Logistics, Zuellig Pharma, smaller specialty β€” Thai pharmaceutical distribution, cold-chain integration; serve multinational, Thai generic, GPO state.[, , , , , ]

GPO, multinational, drivers, regulation: GPO (Government Pharmaceutical Organization), GPO BioPharm Thai vaccine, biologics production, cold-chain integration; Thai-produced AstraZeneca COVID vaccine 2021-2022 leveraged GPO, Siam Bioscience, cold-chain backbone. Multinational pharma (Pfizer, Roche, Sanofi, Novartis, Novo Nordisk, Eli Lilly, Merck, GSK, AstraZeneca, J&J), Thai generic (GPO, Siam Pharmaceutical, LBS, Thai Otsuka) drive demand. Drivers: COVID-19 vaccine surge 2021-2023 transformative for Thai cold-chain capacity, ultra-cold expansion; post-COVID structural demand: mRNA-vaccine pipeline, biologics, insulin/GLP-1, clinical-trial, bio-similar, medical-tourism, private-hospital, retail-pharmacy growth. Regulation: Thai FDA, GDP (Good Distribution Practice), WHO PQS Performance Quality Safety, IATA CEIV Pharma air cargo, cold-chain integrity, temperature-mapping, audit, serialisation.[, , , , ]

Thai FDA, MoPH, DHL, KN, Yusen, Nippon, SCGJWD, DKSH, Zuellig, GPO, WHO, IATA, SCB EIC
Data as of: FY2024-Q1 2026

Thai cold-chain pharma temperature mix (% of FY2024 value)

Ambient-controlled (15-25Β°C)

Share %

46%

Product, use case

Most oral solid, liquid pharmaceutical; controlled-room-temperature

Refrigerated (2-8Β°C)

Share %

32%

Product, use case

Most vaccines, insulin, biologics, GLP-1, mAb

Frozen (-20Β°C to -30Β°C)

Share %

12%

Product, use case

Selective vaccine, biologic, sample

Ultra-cold (-70Β°C to -80Β°C)

Share %

6%

Product, use case

mRNA-vaccine (Pfizer-BioNTech, Moderna), advanced biologics, cell therapy

Cryo, specialty, clinical-trial

Share %

4%

Product, use case

Frozen tissue, cell-bank, research sample

Thai FDA, MoPH, DHL, KN, Yusen, Nippon, SCGJWD, IATA, SCB EIC triangulation
Data as of: FY2024

Analyst framing

Why this report

Thai cold-chain pharma is DHL/KN/Yusen/SCGJWD/DKSH/Zuellig-led, ambient-46%/refrigerated-32% mix, ultra-cold-mRNA-emerging, GDP/WHO-PQS/IATA-CEIV-regulated, COVID-vaccine-driven structural growth.

Unlock the full report

Operator, GPO, ultra-cold, clinical-trial, medical-tourism playbooks, scenarios.
Unlock deep diveΒ·$149-$199

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Related reports

Thailand 3PL Warehouse, Last-Mile Deep Dive

Deep-dive into Thai 3PL, warehouse, last-mile market ~THB 250-300B FY2024 β€” ~4% of GDP logistics spend. Listed: SCGJWD Logistics (SET: SCGJWD post-2023 SCG-JWD merger), NCL International Logistics (SET: NCL), Demco. Foreign-parent: DHL Supply Chain, Yusen Logistics, Nippon Express, Kuehne+Nagel, DB Schenker, Damco, Geodis, DSV. Industrial-estate warehouse: WHA, Amata, FPT, Hemraj, Asia Industrial Estate, IEAT-managed. Last-mile parcel: Kerry Express, Flash Express, JNT Express, Ninja Van, Best Inc, ThailandPost, DHL eCommerce, LINE MAN. Cold-chain, pharma, e-commerce, cross-border ASEAN growing.

Open report β†’

Thailand Cold Chain Logistics Market Intelligence

Thailand cold-chain logistics sector generates approximately THB 45-50B in annual revenue serving food export (seafood, poultry, fruit), domestic food FMCG, pharma temperature-controlled distribution, and a rapidly growing e-grocery segment. SCGJWD Logistics anchors the listed side post-merger; NCL International serves reefer trade; CP Foods and Thai Union operate the largest captive cold chains. Report maps demand drivers, operator concentration, and infrastructure policy (BOI, EEC, PAT reefer capacity).

Open report β†’

Thailand Freight and Shipping Market Intelligence

Thailand freight, shipping, logistics market generates approximately USD 9.5B in FY2024 revenue (SCB EIC, Krungsri, KResearch cross-tabulated with MOT logistics master plan). Mode mix: road haulage 60% (deeply fragmented across 400k+ registered trucks with mid-tier private fleets and TIFFA-aggregated forwarders), ocean container 22% (Laem Chabang ~9M TEU as Thailand's primary deep-sea gateway, Bangkok Port ~1.4M TEU feeder), air cargo 8% (Suvarnabhumi, Don Mueang bellyhold and freighter), rail, cross-border 6% (SRT double-track upgrades, China-Thailand-Laos rail), cold-chain, specialty 4%. Listed operators anchor visible scale: Regional Container Lines (SET: RCL) intra-Asia container shipping, NCL International (SET: NCL) and SCGJWD (SET: SJWD) on integrated logistics, Kerry Express (SET: KEX) on parcel. Private leaders: Flash Express, J&T Express, Thailand Post, DHL Express, FedEx, Nippon Express, Yusen Logistics. Policy anchors: BOI Section 8 logistics, IBC incentives, MOT 10-year master plan targeting 12% logistics-cost-to-GDP, Customs Thai-NSW single window, EEC Laem Chabang Phase 3 PPP, China-Thailand HSR Phase 2.

Open report β†’

Thailand Logistics & Warehousing Market Intelligence

Thailand logistics cost ~13.2% of GDP (down from 14.1% 2019) per NESDC. Listed industrial estate, warehouse: WHA Corporation (SET: WHA, ~3M sqm stock), Amata Corporation (SET: AMATA, Chonburi-anchored), Frasers Property Thailand (SET: FPT, JV platform). Last-mile: Flash Express (private unicorn, 5,000+ distribution points), Kerry/SJWD (SET: SJWD post-2023 merger), Shopee Xpress, J&T Express, Thailand Post, Lazada Logistics. Laem Chabang Port 9M TEU 2024; AOT air cargo 1.3M tonnes; Thailand-China rail Phase 1 2027 target transformative. Land, Multimodal Transport Acts, EEC industrial policy, EV commercial-vehicle transition shape 2026-2028.

Open report β†’

Thailand Cold-Chain Pharma, Vaccine Deep Dive Β· Insight